This is a phase 4 clinical trial studying the effects of the drug Opicapone (ONGENTYS) in patients with Parkinson's Disease who experience "off" episodes with motor fluctuations. The study will involve taking 50 mg of the treatment drug (no placebo) in conjunction with levodopa/carbidopa treatment, while receiving standard care under a neurologist. In addition patients will be asked to complete patient reported outcomes through questionnaires. For more details go here.
The main objective of this study is to evaluate the long term effectiveness of the FDA approved drug Northera in patients with Parkinson's disease (PD), MSA, PAF, NDAN or DBH deficiency who experience symptoms of NOH. Droxidopa increases levels of the hormone norepinephrine which should lead to improved systolic blood pressure and blood flow to the brain, reducing symptoms of dizziness and lightheadedness. For more details go here.
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 65 years and older with Parkinson's disease and Parkinsonism with 2 years of follow-up. A total of 3,500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging. For more details go here.
This study includes wearing an investigational device that can provide symptomatic relief of hand tremors in patients with Parkinson's disease (PD). For more details go here.
Copyright © 2022 Parkinson’s Disease and Movement Disorders Center of Silicon Val - All Rights Reserved.
Powered by GoDaddy Website Builder